Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Titration Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Tardive Dyskinesia

Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Titration Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Tardive Dyskinesia

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2019

At a glance

  • Drugs Valbenazine (Primary)
  • Indications Drug-induced dyskinesia
  • Focus Registrational; Therapeutic Use
  • Acronyms KINECT-2
  • Sponsors Neurocrine Biosciences
  • Most Recent Events

    • 01 Mar 2019 Results of a pooled analysis assessing the effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder in KINECT 2, KINECT 3 and KINECT 3 extension studies, published in the Journal of Affective Disorders
    • 16 Jan 2019 Results of a pooled post-hoc analysis from KINECT 2, KINECT 3 and KINECT 3 extension studies published in a Neurocrine Biosciences Media Release.
    • 27 Apr 2018 Results of a pooled analysis from KINECT, KINECT 2, and KINECT 3 studies assessing minimal clinically important difference (MCID) for Abnormal Involuntary Movement Scale (AIMS) dyskinesia total score in tardive dyskinesia, presented at the 70th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top